REVIEW

Fludarabine in the treatment of chronic lymphocytic leukemia: a review

Francesca Ricci
Alessandra Tedeschi
Enrica Morra
Marco Montillo
Department of Oncology/Haematology, Niguarda Ca’ Granda Hospital, Milan, Italy

Abstract: Fludarabine (FAMP) is the most effective and most extensively studied purine analog in indolent B-cell malignancies. Its use is indicated for first- and second-line treatment of B-cell chronic lymphocytic leukemia (B-CLL). FAMP as a single agent has produced superior response rates and progression-free survival than standard therapy with chlorambucil and alkylator-based regimen. Efficacy of FAMP may be increased by combining this purine analog with other chemotherapeutic and non-chemotherapeutic agents. FAMP and cyclophosphamide combination (FC) has shown promising results with higher overall response and complete response rates than FAMP in monotherapy, although no difference has been detected in survival. Quality of response and eradication of minimal residual disease (MRD) have been reported to be associated with prolonged survival. Eradication of MRD has been achieved by combining FC with mitoxantrone or monoclonal antibody including alemtuzumab or rituximab or both. FAMP has been widely used in non-myeloablative conditioning regimens, often combined with a variety of other cytotoxic agents, with the aim of inducing enough immunosuppression to allow successful engraftment and to exert some pretransplant anti-tumor activity. The current paper provides an overview of use of FAMP as a single agent or as a cornerstone of different therapeutic strategies for treatment of B-CLL patients.

Keywords: fludarabine, chronic lymphocytic leukemia, cyclophosphamide

Introduction

B-cell chronic lymphocytic leukemia (B-CLL) is the most common hematological malignancy in the western world. For several decades the standard treatment for this disease has been chlorambucil (CHL) or cyclophosphamide (CTX), alone or combined with corticosteroids, but complete remissions have been rare with these agents. Other alkylator-based regimens including CVP (CTX, vincristine, prednisone) or CHOP (CTX, doxorubicin, vincristine, prednisone) have been reported to have a comparable efficacy in terms of response and survival. Since the late 1980s the success of cytarabine (ara-C) in the treatment of patients with leukemia and lymphoma has generated interest in other nucleoside analogs. Fludarabine (FAMP), cladribine (2CdA) and pentostatin (DCF) are three chemotherapeutic agents belonging to the family of purine analogs and displaying remarkable activity in malignancies arising from the clonal expansion of lymphocytes, and particularly in B-CLL. These three agents have similar chemical structures and mechanisms of action such as induction of apoptosis. However, they also have significant differences, especially in their interactions with enzymes involved in adenosine and deoxyadenosine metabolism. Different studies suggest that FAMP and 2CdA have similar activity in B-CLL while DCF used alone seems to be less active in this disease.

The most extensively studied of these purine analogs in indolent B-cell malignancies is FAMP. Alone, as well as in combination with DNA-damaging drugs or membrane-targeted antibody, FAMP has a particularly well known efficacy in the treatment of B-CLL.
The current review brings together knowledge of the pharmacokinetics, mechanisms of action and clinical use of FAMP in B-CLL.

**Pharmacokinetics**

FAMP is negatively charged at physiological pH and is therefore unable to enter cells. Thus, it functions as a pro-drug that is converted metabolically by dephosphorylation to the antimetabolite, F-ara-A.

F-ara-A appears to be taken into cells by facilitated transport where it is rephosphorylated to the monophosphate by deoxycytidine kinase and subsequently to the diphosphate and triphosphate. The triphosphate, F-ara-ATP, is the major intracellular metabolite of FAMP and the only metabolite known to have cytotoxic activity. The relatively low concentrations of fludarabine mono- and diphosphate in cells suggests that the activity of deoxycytidine kinase is rate-limiting for triphosphate formation. Several in vitro investigations focused on the relationship between the dose rate of FAMP, the F-ara-A concentrations in plasma, and the cellular accumulation of F-ara-ATP.

The standard infusion rate for treatment of B-CLL, 25 or 30 mg/m² of FAMP infused over 30 min, results in C_max values for F-ara-A that reach 3 to 5 μmol/L at the end of the infusion.

Serial sampling of leukemia cells from patients receiving these standard doses of FAMP has demonstrated that the peak concentrations of F-ara-ATP are achieved 4 hours after start of drug infusion.

The peak F-ara-ATP concentration appeared somewhat later in patients who received doses of 100 to 125 mg/m², suggesting that higher plasma concentrations would support linear accumulation for longer periods. Although there was heterogeneity among individuals for the rate of F-ara-ATP accumulation, the peak concentrations were clearly proportional to the dose of FAMP infused. The retention of F-ara-ATP was also variable among individuals. Elimination was generally monophasic, but the half-life in B-CLL cells ranged from a few hours to several days with a median value of 15 hours. Therefore, F-ara-ATP is a relatively long-lived active metabolite, a characteristic that probably accounts for the observed efficacy of daily administration schedules.

The constancy of the cellular pharmacokinetics of F-ara-ATP in an individual and the heterogeneity in this parameter among patients suggested the possibility that F-ara-ATP cellular pharmacology might be associated with clinical response to FAMP therapy. No correlation was observed, however, between response and F-ara-ATP peak values, elimination rates and total cellular exposure after the first FAMP injection.

Although FAMP is mostly used as an intravenous (iv) formulation, 10 mg FAMP in an immediate release tablet has become available. The bioavailability of oral FAMP is approximately 51%–55% following single and multiple-dose administration, with low intra-individual variation. Systemic bioavailability, C_max and time to C_max are increased slightly with concomitant food intake; the terminal half-life is unaffected. This, and other pharmacokinetic studies, have shown that a once-daily oral FAMP dose of 40 mg/m² would provide a similar systemic exposure to fludarabine 25 mg/m² iv.

Oral FAMP is typically given at a dosage of 40 mg/m² (7–8 tablets) once daily for 5 days, repeated every 4 weeks for up to 6 cycles.

**Mechanism of action**

Every demonstrable cytotoxic mechanism of action of fludarabine requires the presence of F-ara-ATP. The principal action of F-ara-ATP is in the inhibition of DNA synthesis.

Several specific enzymes involved with DNA synthesis are targets for inhibition by F-ara-ATP. In particular, F-ara-ATP competes as an alternative substrate with the normal deoxynucleotide, deoxyadenosine 5'-triphosphate (dATP), inhibiting directly the DNA polymerases. Furthermore, F-ara-ATP is able to inhibit DNA primase, an accessory protein that synthesizes an RNA primer required for initiation of lagging strand synthesis by DNA polymerase.

F-ara-ATP is also an effective inhibitor of ribonucleotide reductase, resulting in lowering of cellular deoxynucleotide pools which are maintained by this enzyme. This would change the ratio of F-ara-ATP to dATP and consequently self-potentiate the DNA synthesis-directed actions of fludarabine.

In addition, F-ara-AMP is incorporated into DNA, particularly at the 3'-terminus, as purine analog. This results in DNA ligase I inability to join it to an adjacent piece of DNA. Moreover, the free triphosphate interacts with this enzyme to block AMP binding and ligation of single strands. These actions on DNA ligase I have important implications for the actions of the drug on the function of this enzyme in DNA replication and repair.

Together these actions are likely to result in complete inactivation of DNA synthesis followed by an initiation...
of programmed cell death that ends in apoptosis of the cell.28–30

Moreover, F-ara-ATP can induce cell death in quiescent cells in the absence of its incorporation into DNA by the activation of the mitochondrial pathway of the apoptotic cascade.31

The mechanism of action of FAMP is reported in Figure 1.

**FAMP in monotherapy**

FAMP has been evaluated as monotherapy in several non-comparative studies conducted in treated and untreated B-CLL patients and at the time it gives the highest response rate reported for a single agent in B-CLL.

One of the initial studies was conducted by Keating et al. This trial included 68 patients with refractory B-CLL who received FAMP as a single agent at 25 to 30 mg/m²/d for 5 days every 4 weeks. Authors described a complete response (CR) rate of 13% with an overall response (OR) rate of 57%. Median overall survival (OS) was 16 months. Toxicities included thrombocytopenia and neutropenia, with 9% of patients experiencing major infections.32

The largest series of patients reporting FAMP activity in relapsed or refractory B-CLL has been reported by Sorensen et al Seven hundred and three patients were treated with 25 mg/m²/d for 5 days every 4 weeks, achieving a complete response (CR) in 3% of cases with an OR rate of 32%. Median OS was 12.6 months. Major toxicities were hematologic in 43% of patients, infections in 22%, and neurotoxicity in 14%.33

Small-scale studies have also been conducted in treatment-naïve patients. The initial study, involving 33 patients who were treated with FAMP (30 mg/m²/d for 5 days, repeated every 4 weeks), reported an OR rate of 79%, with 33% of patients achieving a CR and a further 39% a CR with residual nodules as the only evidence of disease. The response was rapid, usually occurring after 3–6 courses of treatment.34

These findings were confirmed by subsequent studies with standard dose of FAMP which reported an OR rates of 80% to 100%12,35,36 and a median time to disease progression of 33 months.12

As previously reported more recently an oral formulation of FAMP has been developed. Oral FAMP is indicated as second-line therapy in patients who have not responded to, or whose disease has progressed during or after treatment with, at least one standard alkylating agent-containing regimen. Recently, in most European countries oral FAMP has been licensed as first-line treatment in B-CLL.

---

**Figure 1** Metabolism and mechanisms of actions of fludarabine.

**Abbreviations:** A, adenosine; dA, deoxyadenosine; F-ara-A, 9-β-D-arabinosyl-2-fluoroadenine; MP, DP, TP refer to nucleoside 5'-monophosphates, diphosphates and triphosphates, respectively.
In previously treated patients receiving oral FAMP monotherapy OR rates of 46% to 51% were achieved, depending on the response criteria used. Oral FAMP is also an effective first-line treatment. Rossi et al conducted a multicenter open-label study in 81 untreated B-CLL patients receiving oral FAMP 40 mg/m²/d for 5 days every 4 weeks for 6 to 8 cycles. The OR rate was 71.6% (CR 37%) according to International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria and 80.2% (CR 12.3%) using National Cancer Institute-Working Group (NCI) criteria. The OR was comparable with that achieved in a similar historical cohort who received first-line therapy with iv FAMP.

The next logical step was to compare FAMP with traditional alkylator-based therapies in B-CLL patients. Several phase III studies conducted in the USA and Europe have compared the efficacy of iv FAMP as a single agent against that of CHL. Comparing FAMP (25 mg/m²/d for 5 days) to oral CHL (40 mg/m²/d for 1 day) and to the combination of the two drugs (iv FAMP 20 mg/m²/d for 5 days plus oral CHL (20 mg/m²/d for 1 day) as first-line therapy. Patients failing initial therapy were allowed to cross over to the other drug.

FAMP-treated patients had significantly higher OR and CR rates than those treated with CHL (63% vs 37% and 20% vs 4% respectively). The median duration of response and the median progression free survival (PFS) in the FAMP group were significantly longer than in CHL treated patients (25 vs 14 months and 20 vs 14 months respectively). However OS did not differ between the two different treatments. The cross-over planned in this trial may play a role in these results considering that the response rate to CHL among FAMP failures was very low (7%) and the response rate to FAMP among CHL failures was significantly higher (46%). Severe infections and neutropenia were more frequent with FAMP than with CHL. Overall toxic effects were tolerable with the two single-drug regimens, while the combination arm was discontinued during the study because of the toxicity.

FAMP has been compared to CHL plus prednisone in an Italian phase III multicenter study. One hundred forty-seven previously untreated patients with active B-CLL were randomized to receive iv FAMP (25 mg/m²/d for 5 days) or oral CHL (30 mg/m² on days 1 and 15) plus intramuscular prednisone (40 mg/m² on days 1–5 and 15–19). Treatment cycles were repeated every 4 weeks. FAMP was the more effective of the two treatments, resulting in a higher CR rate (47% vs 31%), although OR rates were similar in the two arms. The treatment response was more durable with FAMP than with CHL plus prednisone (28 vs 21 months).

Recently the German CLL Study Group (GCLLSG) initiated a phase III study (CLL5 protocol) to evaluate the effect of FAMP versus CHL in first line therapy of elderly patients with advanced CLL. Long-term follow-up analysis shows that elderly patients have no significant clinical benefit from first-line therapy with FAMP in comparison to CHL. Though higher CR and OR rate FAMP failed to show any benefit in terms of PFS and OS. A possible explanation for this phenomenon is the longer treatment period with CHL (0.4 mg/kg dose escalation up to 0.8 mg/kg every 15 day for up to 12 months), that might prevent earlier relapses. Moreover, in cases of relapse FAMP treated patients received either no treatment at all or more intense regimen in comparison to CHL.

A French Cooperative Group phase III study compared the effectiveness of fludarabine (25 mg/m²/d for 5 days) with CAP regimen (CTX 750 mg/m² iv on day 1, doxorubicin 50 mg/m² iv on day 1, prednisone 40 mg/m² oral on days 1–5) in first and second-line treatment. A total of 6 cycles at 28 day intervals were administered. Higher response rate to FAMP was observed in both untreated (71% vs 60%) and pre-treated (48% vs 27%) cases, although the difference was statistically significant only in pre-treated cases. In the latter group, remission duration and survival did not differ between treatment groups. In untreated cases, on the other hand, fludarabine induced significantly longer remissions than CAP.

In a second French Cooperative Group study 938 treatment-naive patients were randomized to receive FAMP, CAP or CHOP (vincristine 1 mg/m² on day 1, doxorubicin 25 mg/m² iv on day 1, CTX 300 mg/m² oral on days 1–5, prednisone 40 mg/m² iv oral on days 1–5) repeated every 4 weeks. The response rate was greater in patients treated with FAMP and CHOP compared to CAP. There was no difference in PFS and OS between the groups. Time of second-line therapy was significantly longer in the FAMP group while the purine analog was better tolerated compared to CHOP and CAP. Consequently patients treated with fludarabine enjoyed a better quality-adjusted time without symptoms or toxicity.

Some investigators attempted to identify factors that predict a good response to FAMP. In an M.D. Anderson Cancer Center study of 264 pre-treated and untreated B-CLL
patients receiving FAMP and prednisone a multivariate analysis-derived prognostic model for response to treatment was proposed and 4 factors were found to be significantly associated with worse response: Rai III-IV stage disease, prior therapy, older age, and low albumin levels.44

Dhöner et al studied mononuclear cells from 100 patients (90 B-CLL, 7 B-cell prolymphocytic leukemia, 3 Waldenström macroglobulinemia) using fluorescence in situ hybridization (FISH) with a genomic p53 DNA probe. Seventeen of the 100 patients exhibited a monoallelic p53 gene deletion by FISH. Fifty patients received therapy with purine analogs. The response to therapy depended strongly on the presence of a p53 gene deletion. None of the 12 patients with a deletion responded to therapy with FAMP or pentostatin, while 20 of 36 patients without a deletion who were assessable for response achieved a remission (p < 0.001). The difference in survival probabilities from the time of diagnosis and from the start of treatment with purine analogs between the two groups was highly significant (p < 0.001). In multivariate analysis, p53 gene deletion was the strongest prognostic factor for survival. In conclusion, p53 gene deletion predicts for non-response to therapy with purine analogs and for poor survival in B-CLL.47 More recently, Valgañón et al analyzed the aberrations in p53, including the methylation status of its promoter, in 54 patients with advanced stage B-CLL who received FAMP as first-line. They confirmed that the abnormalities of p53, either methylation or deletion, were associated with short survival and non-response to therapy.46

The experiences with FAMP in monotherapy are reported in Table 1.

**FAMP in combination treatment**

Efficacy of FAMP may be increased combining this purine analog with other agents. Indeed, FAMP has been shown to have a biochemical modulating effect on other chemotherapeutic agents in vitro, for example CTX,47,48 ara-C49,50 cisplatin51,52 and mitoxantrone.53,47 In view of this synergistic/biochemical modulating effect, attempts to improve the CR and relapse rate have been explored with the use of FAMP in combination with other chemotherapeutic agents. Studies exploring efficacy and safety FAMP-based schedule are listed in Tables 2, 3 and 4.

**FAMP with alkylating agents**

Taking into account the wide use of CHL in B-CLL the combination of FAMP plus CHL has been explored in clinical trials.54,55 This treatment did not show a significant improvement in response rate or survival compared with FAMP alone. Furthermore, treatment with FAMP plus CHL appeared to be associated with a higher incidence of adverse events compared with either FAMP or CHL alone.

In particular in the CALGB study49 as previously mentioned, FAMP treatment was compared to CHL and to the combination of the two drugs as first-line therapy. Assignment of patients to the FAMP plus CHL group was stopped when a planned interim analysis revealed excessive toxicity and a response rate that was not better than the rate with FAMP alone.39,56

FAMP and CTX is by far the best investigated FAMP-combination. It has been examined in several trials, including trials with additional filgrastim support and with mitoxantrone added to the regimen.

One of the first non-comparative studies was conducted by O’Brien et al in 128 untreated and pre-treated patients with B-CLL who received FAMP 30 mg/m²/d iv for 3 days and CTX at either 500 mg/m²/d for 3 days, 350 mg/m²/d for 3 days, or 300 mg/m²/d for 3 days. The CTX dose was decreased because of myelosuppression in the early part of the study. Patients were stratified into four groups according to pretreatment status, that is, untreated, treated with alkylating agents, treated with and responsive to FAMP with or without alkylating agents but relapsing, and treated with and refractory to FAMP with or without alkylating agents.

The OR and the CR rates were 88% and 35% respectively for previously untreated patients, compared with 85% and 15% in patients previously treated with alkylating agents. In the subgroup of patients refractory to FAMP, an OR rate of 39% suggests that the combination of FAMP with CTX may be synergistic in this group. The median time to progression was 12 to 38 months in patients who had received prior therapy. In previously untreated patients, the median time to progression and survival duration had not been reached after a median follow-up of 41 months.57

Similar results in terms of OR and CR rates were reported in a smaller study conducted in treatment-naïve patients by Flinn et al. In this study combination of FAMP and CTX were investigated with the filgrastim support FAMP 20 mg/m²/d iv for 5 days and CTX 600 mg/m²/d iv on day 1 were followed by filgrastim 5 μg/kg for 10–14 days starting around day 8. Treatment was repeated every 28 days for a maximum of six cycles. An interesting finding was the reduced incidence of leukocytopenia, and the increased incidence of thrombocytopenia and anemia in patients receiving G-CSF in addition to the FAMP plus CTX combination.58

FAMP associated to CTX has also been investigated in 3 recently published comparative studies.
Table 1 Results of clinical trials on B-CLL with fludarabine monotherapy

| References | Comp study | No of evaluable patients | Prior therapy | Treatment regimen | Clinical response | Survival/duration of response |
|------------|------------|--------------------------|---------------|-------------------|------------------|-----------------------------|
| Keating et al\(^3\) | no | 68 | yes | FAMP 25–30 mg/m\(^2\) iv \(\times\) d1–5 q 4 wk | 13 | 57 | 16 mo median OS |
| Keating et al\(^12,34\) | no | 33 | no | FAMP 30 mg/m\(^2\) iv \(\times\) d1–5 q 4 wk | 33 | 79 | 33 mo median PFS |
| Clavio et al\(^35\) | no | 32 | no | FAMP 25 mg/m\(^2\) iv \(\times\) d1–5 q 4 wk | 16 | 100 | na |
| Sorensen et al\(^33\) | no | 703 | yes | FAMP 25 mg/m\(^2\) iv \(\times\) d1–5 q 4 wk | 3 | 32 | 12.6 mo median OS |
| Steltano et al\(^36\) | no | 47 | yes (64%) | FAMP 25 mg/m\(^2\) iv \(\times\) d1–5 q 4 wk or FAMP 25 mg/m\(^2\) iv \(\times\) d1–4 q 3 wk | 34 | 74 | 35.7 mo median OS |
| Leporrier et al\(^41\) | yes | 924 | no | FAMP 25 mg/m\(^2\) iv \(\times\) d1–5 q 4–6 wk (n = 336) CAP (n = 237) CHOP (n = 351) | 40 | 71 | 69 mo median OS |
| Rai et al\(^39\) | yes | 509 | no | FAMP 25 mg/m\(^2\) iv \(\times\) d1–5 q 4 wk (n = 179) CHL 40 mg/m\(^2\) os \(\times\) d1 q 4 wk (n = 193) FAMP 10–20 mg/m\(^2\) iv \(\times\) d1–5 + CHL 15–20 mg/m\(^2\) os \(\times\) d1 q 4 wk (n = 137) | 20 | 63 | 25 mo median DFS, 20 mo median PFS, 66 mo median OS |
| Jhonson et al\(^40\) | yes | 100 | no | FAMP 20 mg/m\(^2\) iv \(\times\) d1–5 q 4w (n = 52) CAP (n = 48) | 23 | 48 | na |
| Spriano et al\(^42\) | yes | 115 | no | FAMP 25 mg/m\(^2\) iv \(\times\) d1–5 q 4 wk CHL 30 mg/m\(^2\) d1 and 15 + PDN 40 mg/m\(^2\) im on days 1–5 and 15–19 | 47 | 70 | 28 mo median PFS |
| Rossi et al\(^38\) | no | 81 | no | FAMP 40 mg/m\(^2\) os \(\times\) d1–5 q 4 wk | 12.3 | 80.2 | 841 d median PFS |
| Boogerts\(^37\) | no | 78 | yes | FAMP 40 mg/m\(^2\) os \(\times\) d1–5 q 4 wk | 17.9 | 51.3 | na |
| Eichhorst\(^43\) | yes | 206 | yes | FAMP 25 mg/m\(^2\) iv \(\times\) d1–5 q 4 wk CHL 0.4 mg/kg dose escalation up to 0.8 mg/kg every 15 day for up to 12 months | 8 | 86 | 18.7 mo median PFS, 45.9 mo median OS |
| | | | | | 0 | 59 | 17.8 mo median PFS, 63.6 mo median OS |

Abbreviations: Comp, comparative; CR, complete remission; OR, overall response; DFS, disease-free survival; OS, overall survival; PFS, progression-free survival; FAMP, fludarabine; PDN, prednisone; CHL, chlorambucil; CAP, cyclophosphamide + doxorubicin + prednisone; CHOP, vincristine + doxorubicine + cyclophosphamide + prednisone; d, days; mo, months; wk, weeks; q, every; iv, intravenous; os, oral; im, intramuscular; na, not applicable.
In the first comparative phase III trial, GCLLSG CLL4 study, 362 treatment-naïve patients with advanced B-CLL, were randomly assigned to receive either FAMP (25 mg/m²/d for 5 days iv, repeated every 28 days) or FC combination therapy (FAMP 30 mg/m²/d plus CTX 250 mg/m²/d for 3 days iv, repeated every 28 days). Both regimens were administered up to a maximum of 6 courses.

Patients receiving FC combination chemotherapy showed a significantly higher CR rate (24%) and OR rate (94%) compared with FAMP alone (7% and 83%). FC treatment also resulted in longer median PFS (48 vs 20 months) and longer treatment-free survival (37 vs 25 months). At the time of writing, no difference in median OS has been observed. FC caused significantly more thrombocytopenia and leukocytopenia but did not increase the number of severe infections. No significant difference was detected in health-related quality of life between FAMP and FC-treated patients. In a recent update of the outcome of patients enrolled in the CLL4 GCLLSG trial the analysis according to clinical and biologic parameters has been presented. Investigating a specific treatment effect PFS was longer after FC for the following subgroups: unmutated immunoglobulin heavy chain (IgVH) gene, no aberration, del(11q), unmutated TP53, CD38 < 7%, and beta2microglobulin <5 mg/L. OS was significantly longer after FC only in the subgroups with 11q-, +12, and unmutated TP53. However, in comprehensive multivariate analysis of TP53 mutations, del (11q), thymidine kinase >10 remained a predictor for PFS and OS independently of the improvement by FC.

Results of a second comparative study were reported by Flinn et al. This is a phase III randomized Intergroup trial comparing FC regimen versus FAMP alone in 278 patients receiving their first chemotherapy regimen for B-CLL. Dosages of FC schedule were the same as the first study. Authors confirmed the superiority of FC arm in terms of OR (74.3% vs 59.5%), CR (23.4% vs 4.6%) and PFS (31.6 vs 19.2 months). OS was not different between the two arms. Regarding toxicity FAMP and CTX caused additional hematologic toxicity, including more severe thrombocytopenia, but it did not increase the number of severe infections.

The third randomized study was published by Catovsky et al. Seven hundred and seventy-seven patients with previously untreated B-CLL requiring treatment were randomly assigned to FAMP (25 mg/m²/d iv or 40 mg/m²/d orally for 5 days) or FC schedule (FAMP 25 mg/m²/d iv and CTX 250 mg/m²/d iv for 3 days or orally over 5 days with FAMP 24 mg/m²/d and CTX 150 mg/m²/d) for 6 courses, or CHL (10 mg/m²/d for 7 days) until maximum response or up to 12 courses. Analysis was by intention to treat. There was no significant difference in OS between patients given FC, FAMP or CHL. CR and OR rates were better with FC than with FAMP (CR 38% vs 15%, respectively; OR 94% vs 80%, respectively), which were in turn better than with CHL (CR 7%, OR 72% respectively). PFS at 5 years was significantly better with FC (36%) than with FAMP (10%) or CHL (10%). FC was the best combination for all ages, including patients older than 70 years, and in prognostic groups defined by IgVH gene mutation status and cytogenetics. Interestingly, the same PFS has been reported after FAMP alone and after CHL. The dose of CHL used in the LRFCLL4 trial was almost double that used by Rai et al in the earlier comparison, suggesting that when a higher dose is used FAMP has no advantage over CHL.

A meta-analysis of these data and those of two published phase III trials showed a consistent benefit for the FC regimen in terms of PFS. FC schedule was also investigated using FAMP and CTX as oral formulation.

Cazin et al reported in 75 treatment-naïve patients with B-CLL an OR and a CR rate of 75% and 53% respectively, and a median PFS of 5 years, administering oral FAMP (30 mg/m²/d days 1–5) plus oral CTX (200 mg/m²/d days 1–5) every 28 days for 6 courses. Moreover, Laurenti et al tested the efficacy and safety of oral FAMP and CTX as front-line therapy and assessed the influence of IgVH gene mutation status, interphase cytogenetic abnormalities, and expression of ZAP-70 and CD38 on clinical outcome. Treatment schedule consisted of oral FAMP (30 mg/m²) and oral CTX (250 mg/m²) for 3 consecutive days every 4 weeks for 6 cycles. High risk cytogenetic group was defined by the abnormality del(11q22.3) or del(17p13.1). Among the 35 evaluable patients, 14 (40%) obtained a CR and 13 (37%) a partial response (PR). The median PFS was 23 months and median time to re-treatment (TTR) was 38 months. A significantly lower OR rate (43% vs 85%), a shorter PFS (22 vs 27 months), and a shorter TTR (22 vs 40 months) were noticed in the ‘high risk’ cytogenetic abnormalities group; TTR was also shorter in IgVH-unmutated than in IgVH-mutated patients (26 vs 41 months).

FAMP with anthracyclines or anthraccenedione

The addition of mitoxantrone to FAMP did not markedly increase the response rate to FAMP, but the combination of FAMP with CTX and mitoxantrone (FCM) showed promising results. The efficacy of two slightly different
Table 2 Results of clinical trials on B-CLL with fludarabine in combination with alkylating agents

| References | Comp study | No of evaluable patients | Prior therapy | Treatment regimen | Clinical response | Survival/duration of response |
|------------|------------|--------------------------|---------------|-------------------|------------------|-------------------------------|
|            |            |                          |               |                   |                  |                               |
| **FAMP + CHL** |            |                          |               |                   |                  |                               |
| Elias et al54 | no         | 17                       | yes           | FAMP 10–20 mg/m² iv × d1–5 + CHL 15–20 mg/m² iv × d1 4 wk | 6                  | 53 na                        |
| Weiss et al55 | no         | 15                       | yes           | FAMP 10–20 mg/m² iv × d1–5 + CHL 20 mg/m² iv × d1 and d15 4 wk | 7                  | 27 na                        |
| **FAMP + CTX** |            |                          |               |                   |                  |                               |
| O’Brien et al57 | no         | 128                      | Yes (some)    | FAMP 30 mg/m² iv × d1–3 + CTX 300–500 mg/m² iv × d1 3 q–6 wk | 17                 | 74 12–38 mo median OS     |
| Hallev et al120 | no         | 32                       | Yes (some)    | FAMP 30 mg/m² iv × d1–3 + CTX 250 mg/m² iv × d1 3 q 4 wk | 16                 | 90 na                        |
| Eichhorst et al59 | yes        | 328                      | no            | FAMP 25 mg/m² iv × d1–5 q 4 wk (n = 164) FAMP 30 mg/m² iv × d1–3 + CTX 250 mg/m² iv × d1–3 q 4 wk (n = 164) | 7                  | 83 20 mo median DFS       |
| Flinn et al61 | yes        | 278                      | no            | FAMP 20 mg/m² iv × d1–5 + CTX 600 mg/m² iv × d1 FAMP 25 mg/m² iv × d1–5 q 4 wk | 23                 | 74 32 mo median PFS, OS 79% at 2 yrs |
| Catovsky et al62 | yes        | 777                      | no            | FAMP 25 mg/m² iv or 40 mg/m² os × d1–5 q 4 wk FAMP 25 mg/m² iv × d1–3 or 24 mg/m³ os × d1–5 + CTX 250 mg/m² iv × d1–3 or 150 mg/m² os × d1–5 q 4 wk | 15                 | 80 PFS 36%, OS 2% at 5 yrs |
| Cazin et al63 | no         | 76                       | no            | FAMP 30 mg/m² os × d1–5 + CTX 200 mg/m² os × d1–5 q 4 wk | 7                  | 72 PFS 10%, OS 59% at 5 yrs |
| Laurenti et al64 | no         | 37                       | no            | FAMP 30 mg/m² os × d1–3 + CTX 250 mg/m² os × d1–3 q 4 wk | 40                 | 77 23 mo median PFS       |
| Flinn et al65 | no         | 36                       | no            | FAMP 20 mg/m² iv × d1–5 + CTX 600 mg/m² iv × d1 + G-CSF 5 mg/kg × db18/22 q 4 wk | 42                 | 64 38 mo median TTR OS 89% at 30 mo |

**Abbreviations:** Comp, comparative; CR, complete remission; OR, overall response; DFS, disease free survival; OS, overall survival; PFS, progression free survival; TTR, time to retreatment; DoR, duration of response; FAMP, fludarabine; CTX, cyclophosphamide; CHL, chlorambucil; d, days; mo, months; wk, weeks; q, every; iv, intravenous; os, oral; na, not available.
treatment regimens was assessed in a clinical trial in recurrent or resistant B-CLL patients. Twenty-three patients received iv FAMP 25 mg/m² on days 1–3, CTX 600 mg/m² on day 1 and mitoxantrone 8 mg/m² on day 1, at 4-week intervals for up to 6 courses. A further 37 patients received the same FAMP regimen plus CTX 200 mg/m²/d on days 1–3 and mitoxantrone 6 mg/m² on day 1. The OR was 78%, including 50% CR and 28% PR. Absence of minimal residual disease (MRD) was detected in 17% of patients by cytofluorimetric and molecular methods. The median duration of response was 19 months and the actuarial median survival duration was 41 months. The incidence of myelosuppression and infection was noticeably higher in this study (neutropenia or leukocytopenia = 90%) with corresponding infection rates of 23%. Recently the same authors reported the results in a larger group of B-CLL patients receiving as initial therapy the same schedule of treatment using mitoxantrone 6 mg/m². The OR, MRD-negative CR, MRD-positive CR, nodular PR (nPR), and PR rates were 90%, 26%, 38%, 14%, and 12%, respectively. Median response duration was 37 months. Patients with del(17p) failed to attain CR. Patients achieving MRD-negative CR had a longer response duration and OS than patients with an inferior response. Low serum LDH levels, low ZAP-70 expression, and mutated IgV(H) genes explained by the infection prophylaxis with fluconazole, acyclovir, trimethoprim/sulfamethazole and G-CSF.

FAMP has also been investigated in combination with other chemotherapeutic agents. The majority of these studies were small, with less than 50 enrolled patients. Disappointing results were achieved when FAMP was combined with doxorubicin (with or without prednisone) with an OR rate of 55% and a CR rate of only 3%. Higher response rate was reported in untreated and pre-treated patients receiving FAMP associated to epirubicin in a phase II study.

In a phase III, randomized trial, FAMP was compared with FAMP plus epirubicin in the same setting. Preliminary results in 150 patients showed that the combination achieves statistically higher response rates and longer duration of event free survival; however this does not translate in a statistically significant OS benefit.

FAMP with ara-C with or without cisplatin
FAMP has also been tested in association with ara-C yielding an OR rate of 5% in FAMP refractory patients. The addition of cisplatin to this regimen improved the OR slightly to 19% in a phase II study of 41 pre-treated patients. Notably, the combination of FAMP with ara-C or cisplatin was associated with particularly high toxicities in terms of cytopenia and myelosuppression.

FAMP and non-chemotherapeutic agents
In the last 2 years the FAMP plus CTX schedule has also been tested in association with new non-chemotherapeutic drugs resulting previously effective in the treatment of other hematological malignancies. As expression of Bcl-2 protein is associated with chemotherapy resistance and decreased survival in B-CLL, O’Brien et al evaluated whether oblimersen, antisense oligonucleotides would improve response to FC chemotherapy in patients with relapsed or refractory B-CLL. Two hundred and forty-one patients receiving at least one prior FAMP-containing regimen were randomly assigned to 28-day cycles of FAMP 25 mg/m²/d plus CTX 250 mg/m²/d administered iv for 3 days with or without oblimersen 3 mg/kg/d as a 7-day continuous iv infusion (beginning 4 days before chemotherapy) for up to 6 cycles. CR/nPR rates were significantly higher in the oblimersen arm (17% vs 7%) and achievement of CR/nPR was correlated with both an extended time to progression and survival. In patients who remained sensitive to FAMP, oblimersen was associated with a 4-fold increase in the CR/nPR rate and a significant survival benefit.

Thalidomide has been shown to inhibit production of TNF-alpha. Elevated levels of TNF-alpha have been associated with progressive disease in patients with B-CLL. Chanan Khan et al conducted a phase 1/2 clinical trial to determine the safety and efficacy of combining thalidomide with FAMP in patients with treatment-naïve B-CLL. Patients received 6 months of continuous daily thalidomide with standard monthly doses of FAMP. Three dose levels of thalidomide (100, 200, and 300 mg) were studied. Thirteen patients were enrolled in the phase 1 component of the study. Dose-limiting toxicity was not reached. OR rate was 100% with 55% of patients achieving CR. At a median follow-up of 15 months none of the patients had a relapse and the median time to disease progression had not yet been reached. Responses were noted at all dose levels. Disappointing results have been reported in a small Italian study in which 5 pre-treated B-CLL
Table 3 Results of clinical trials on B-CLL with fludarabine in combination with anthracyclines or anthracenedione

| References            | Comp study | No of evaluable patients | Prior therapy | Treatment regimen                                                                 | Clinical response | Survival/duration of response |
|-----------------------|------------|--------------------------|---------------|-------------------------------------------------------------------------------------|-------------------|------------------------------|
| **FAMP + Dox + PDN**  | no         | 29                       | yes           | FAMP 30 mg/m² d1–3 or 25–30 mg/m² d1–4 + Dox 50 mg/m² d1 ± PDN 30 mg/m² d1–5 q 4 wk | 10                | 46                           | 28 mo median OS              |
| Robertson et al⁹⁶     | no         | 29                       | yes           | FAMP 25 mg/m² d1–5 + EPI 25 mg/m² d4–5 q 4 wk                                       | 32                | 82                           | 19 mo median PFS              |
| Rummel et al⁹⁷        | yes        | 150                      | yes (some)    | FAMP 25 mg/m² d1–5 + EPI 25 mg/m² d4–5 q 4 wk                                       | 29                | 88                           | 30 mo median EFS, 76 mo median OS |
|                       | yes        | 150                      | yes (some)    | FAMP 25 mg/m² d1–5 + EPI 25 mg/m² d4–5 q 4 wk                                       | 9                 | 73                           | 19 mo median EFS, 63 mo median OS |
| **FAMP + MIT**        | no         | 88                       | yes (some)    | FAMP 30 mg/m² × d1–3 + MIT 10 mg/m² d1                                               | 20 1st line       | 83 1st line                   | 2 yrs median PFS              |
| Tsimberidou et al¹¹¹  | no         | 88                       | yes (some)    |                                                                                     | 7 2nd line        | 55 2nd line                   |                              |
| **FAMP + CTX + MIT + ara-C + Dex** | no | 31                       | yes           | FAMP 25 mg/m² iv d at 0, 24 and 48 h + Ara-C 1 g/m² iv at 4 h or at 4 h and 28 h + MIT 10 mg/m² iv at 6 h + Dex 20 mg iv d on d1–3 q 4 wk | 60                | 70                           | 28 mo median PFS, OS 68% at 67 mo |
| Mauro et al⁶⁷         | no         | 31                       | yes           | FAMP 25 mg/m² iv d at 0, 24 and 48 h + Ara-C 1 g/m² iv at 4 h or at 4 h and 28 h + MIT 10 mg/m² iv at 6 h + Dex 20 mg iv d on d1–3 q 4 wk | 60                | 70                           | 28 mo median PFS, OS 68% at 67 mo |
| **FAMP + CTX + MIT**  | no         | 60                       | yes           | FAMP 25 mg/m² iv × d1–3 + CYC 600 mg/m² iv × d1 or 200 mg/m² iv × d1–3 + MIT 6–8 mg/m² × d1 q 4 wk | 50                | 78                           | 19 mo median DoR, 42 mo median OS |
| Bosch et al⁶⁵         | no         | 60                       | yes           |                                                                                     | 50                | 78                           | 19 mo median DoR, 42 mo median OS |
| Bosch et al⁶⁶         | no         | 69                       | no            | FAMP 25 mg/m² iv × d1–3 + CTX 200 mg/m² iv × d1–3 + MIT 6 mg/m² × d1 q 4 wk           | 64                | 90                           | 37 mo median PFS              |

**Abbreviations:** Comp, comparative; CR, complete remission; OR, overall response; OS, overall survival; PFS, progression-free survival; DoR, duration of response; EFS, event-free survival; FAMP, fludarabine; CTX, cyclophosphamide; MIT, mitoxantrone; Dox, doxorubicin; Dex, desametaxone; ara-C, cytarabine; EPI, epirubicin; PDN, prednisone; d, days; mo, months; wk, weeks; q, every; iv, intravenous; os, oral.
patients were enrolled. Four patients had to be withdrawn from the study due to disease progression in 3 cases while a severe neurological toxicity was detected in 1 patient.75

**FAMP in combination with monoclonal antibodies**

The emergence of monoclonal antibodies has expanded the possibilities and strategies for therapy in patients with B-CLL.

There are several reasons for combining chemotherapy with monoclonal antibodies. First, there is little overlapping toxicity. Second, chemotherapy and monoclonal antibodies cause cell death by different mechanisms, and B-CLL cells that are resistant to one mechanism of cell killing may be susceptible to the other. Third, there is preclinical evidence to suggest that chemotherapy and monoclonal antibodies may act in a synergistic manner. Rituximab is a chimeric monoclonal antibody that binds to CD20 and is currently approved for the treatment of patients with relapsed low-grade lymphoma. Alemtuzumab is an anti-CD52 antibody approved for B-CLL patients who have failed prior therapy with FAMP. More recently FDA granted regular approval and expanded labeling for alemtuzumab as single-agent treatment for B-CLL.

Rituximab has limited activity as a single agent in B-CLL, with reported OR rates ranging from 7% to 35% in relapsed patients.76,77 Dose intensification strategies have been used, with higher response rates achieved. However, the majority of responses were partial and of brief duration.76

Because of these findings, rituximab is more often used in combination with other chemotherapeutic agents, such as FAMP or FAMP plus CTX.78–81

Cancer and Leukemia Group B (CALGB) and the US Intergroup investigated in multicenter phase 2 trial (CALGB 9712) safety and efficacy of a immuno-chemotherapeutic regimen combining FAMP and rituximab (FR) in treatment-naive B-CLL. Patients were randomized to receive either 6 courses of FAMP (one course every 28 days) concurrently with rituximab followed 2 months later by 4-weekly doses of rituximab for consolidation therapy or sequential FAMP alone followed 2 months later by rituximab consolidation therapy. In this study rituximab administered concurrently with FAMP in previously untreated B-CLL patients demonstrates marked clinical efficacy in terms of OR (90% vs 77%) and CR (47% vs 28%) rates and acceptable toxicity. However no differences were detected in term of PFS and OS between the two arms.79

The same authors retrospectively compared efficacy data of the CALGB 9712 study with the CALGB 9011 study that compared FAMP as single agent to CHL. In multivariate analyses controlling for pre-treatment characteristics, the patients receiving FAMP and rituximab had a significantly better PFS and OS than patients receiving FAMP therapy. Two-year PFS probabilities were 0.67 vs 0.45, and 2-year OS probabilities were 0.93 vs 0.81. Infectious toxicity was similar between the two treatment approaches.82 These comparative data are retrospective and could be confounded by differences in supportive care or dissimilar enrolment of genetic subsets on each trial.

A multivariate analysis examining the type of treatment (addition or not of rituximab) and other pre-treatment clinical and laboratory features demonstrated that inclusion of rituximab was as good as or better than leukocytosis and age at predicting PFS and OS.82

More recently the M.D. Anderson Cancer Group published results obtained with the combination of FAMP, CTX and rituximab (FCR) in previously treated B-CLL patients.

Treatment consisted of rituximab 375 mg/m² day 1 of course 1 and 500 mg/m² day 1 of courses 2 to 6; FAMP 25 mg/m²/d days 2 to 4 of course 1 and days 1 to 3 of courses 2 to 6; and CTX 250 mg/m²/d days 2 to 4 of course 1 and days 1 to 3 of courses 2 to 6. Courses were repeated every 4 weeks. CR was achieved in 25% of 177 patients enrolled, with an OR rate of 73%. Molecular remission was achieved in a third of patients who obtained CR.80

| Table 4 Results of clinical trials on B-CLL with fludarabine with ara-C with or without cisplatin |
|References| Comp study| No of evaluable pts| Prior therapy| Treatment regimen| Clinical response| Survival/duration of response |
|---|---|---|---|---|---|---|
|FAMP + ara-C| no| 15| yes| FAMP 30 mg/m² d1 + ara-C 500–1000 mg/m² d1 q 4 wk| 0| 5| 9 mo median OS |
|FAMP + ara-C + Cis| no| 41| yes| FAMP 30 mg/m² d1 + ara-C 500 mg/m² d1–4 ± ara-C Cis 25 mg/m² d1 q 4 wk| 0| 19| 6 mo median OS |

Abbreviations: Comp, comparative; CR, complete remission; OR, overall response; OS, overall survival; FAMP, fludarabine; ara-C, cytarabine; Cis, cisplatin; d, days; mo, months; wk, weeks; q, every; iv, intravenous; os, oral.
Keating et al.\textsuperscript{81} tested FCR schedule in 224 previously untreated B-CLL patients. Results and safety were historically compared with the previously reported data on a group of patients treated with FC.\textsuperscript{87} The OR and CR rates were 95% and 70% respectively. The CR rate compared favorably with that achieved in the historical experience with FC (35% vs 70%), while no differences were detected in OR rate (88% vs 95%).

Two thirds of patients, receiving FCR schedule, evaluated with two-color flow cytometry, had less than 1% CD5+/CD19+ coexpressing cells in bone marrow after therapy. Recently the authors published an update of long-term results reporting a 6-year overall and failure-free survival of 77% and 51%, respectively. Median time to progression was 80 months.

Pre-treatment characteristics independently associated with inferior response were age 70 years or older (14% of patients), beta2-microglobulin twice the upper limit of normal (2N) or more (43% of patients), white cell count 150 × 10^9/L or more (17% of patients), abnormal chromosome 17 (4% of patients), and LDH 2N or more (2% of patients). No pre-treatment characteristic was independently associated with decreased CR duration.\textsuperscript{83}

Recently the same authors reported no significant impact of the mutational status on the CR rate and on long-term survival in patients treated with FCR. However in patients with unmutated IgVH a shorter remission duration was observed.\textsuperscript{84}

Interestingly in a multivariate analysis of patients receiving FAMP-based therapy at M.D. Anderson Cancer Center Group, FCR therapy emerged as the strongest independent determinant of survival.\textsuperscript{85}

In order to validate the observation of a single center study that FCR combination improved the outcome of untreated B-CLL patients the GCLLSG initiated a multicenter, multinational phase III trial to evaluate the efficacy and tolerability of FCR vs FC as first-line treatment of patients with advanced B-CLL.

In this study 817 patients were enrolled between July 2003 and March 2006. After a median observation time of 25.5 months, 761 patients (FCR 390; FC 371) were evaluable for response and 787 patients (FCR 400; FC 387) for PFS and all for OS. The OR and CR rates were significantly higher in the FCR arm (95% and 52%) than in FC (88% and 27%). PFS was 76.6% at 2 years in the FCR arm and 62.3% in the FC arm with a trend for an increased OS rate in the FCR arm (91% vs 88% at 2 years).\textsuperscript{86}

The major toxicity related to FCR treatment was grade 3/4 neutropenia while persistent cytopenia following completion of therapy and lasting more than 3 months was reported in 19% of patients treated. However, following recovery of blood counts, recurrent late cytopenia episodes occurred in 28% of cases, predominantly during the first year of remission, with 1 and 6 year incidences of 18% and 23%, respectively.\textsuperscript{83} One approach to decrease neutropenia without compromising efficacy could be by reducing the doses of FAMP and CTX and increasing the cumulative dose of rituximab. Foon et al. conducted a phase II study for previously untreated advanced B-CLL patients using a so-called FCR-Lite schedule (FAMP 20 mg/m²/d days 1–3, CTX 150 mg/m²/d days 1–3, rituximab 500 mg/m²/days 1 and days 14 every 4 weeks; maintenance rituximab 500 mg/m² every 3 months until progression).

Fifty patients were enrolled to receive treatment and 48 were evaluable for response. Among them CR rate was 77%, PR rate was 23% with an OR rate of 100%. Patients who achieved CR were tested by two-color flow cytometry and 97% of patients had <1% CD5+/CD19+ cells in their bone marrow after therapy. This experience suggests that FCR-Lite is highly effective with considerably less grade 3/4 neutropenia than standard FCR. Complete responders had no detectable CD5+/CD19+ cells in their bone marrow following FCR-Lite.\textsuperscript{86}

As previously mentioned a synergistic effect has been demonstrated between FAMP, ara-C and cisplatin.\textsuperscript{72} The M.D. Anderson Cancer Group explored the efficacy of FAMP plus rituximab when associated to oxaliplatin and ara-C in OFAR regimen that consisted of increasing doses of oxaliplatin (17.5, 20, or 25 mg/m²/d on days 1–4, phase I), FAMP 30 mg/m² on days 2 to 3, ara-C 1 g/m² on days 2 to 3, rituximab 375 mg/m² on day 3 of cycle 1 and day 1 of subsequent cycles, and pegfilgrastim 6 mg on day 6, every 4 weeks for a maximum of 6 courses.

In a phase I–II trial 50 patients were treated (20 patients had Richter’s syndrome, and 30 had a FAMP refractory B-CLL) with OFAR schedule. This regimen was highly active with an OR rate of 50% in Richter’s syndrome and of 33% in FAMP-refractory B-CLL. Satisfactory response was also achieved in 7 of the 20 patients with 17p deletion (35%) and in 2 of 7 patients with 11q deletion (29%).\textsuperscript{87}

Based upon the excellent previously mentioned results obtained with FCM,\textsuperscript{88} the same group of authors have built up a new chemoimmunotherapy combination with rituximab plus FCM (R-FCM). In a phase II study 72 patients under the age of 70 with active B-CLL according to NCI and IWCLL criteria received R-FCM regimen as initial treatment followed by a maintenance therapy phase consisting of rituximab every 3 months for 2 years. Although based on two
different phase II studies that preclude a completely valid statistical comparison, the CR rate obtained with R-FCM (82%, of which 46% MRD-negative CR) favorably compares with that achieved with FCM (CR 64%, MRD-negative CRs 38%). In summary the 82% CR rate obtained with R-FCM is among the highest ever reported for any form of therapy for B-CLL and treatment toxicity was acceptable and manageable. Based on these results, R-FCM warrants further investigation, particularly in randomized clinical trials.

In the scene of monoclonal antibodies available for B-CLL treatment alemtuzumab has certainly shown superior activity when compared with rituximab as monotherapy. In addition, alemtuzumab is most effective in reducing leukemia counts and bone marrow disease and less effective in shrinking bulky lymphadenopathy. Alemtuzumab has been studied in FAMP refractory B-CLL patients, in previously untreated patients, in patients with MRD persistence after FAMP-based regimen, and concurrent with FAMP and rituximab. Apart from the infusional reaction related to iv administration of alemtuzumab, the development of opportunistic infections are reported. Antibacterial and antiviral prophylaxis is recommended in all patients receiving alemtuzumab therapy.

The first experiment was conducted by Kennedy et al who treated 6 patients with B-CLL who were refractory to both alemtuzumab and FAMP used as single agents, and found that 5 of 6 patients responded to combination therapy, including 1 CR. However, long-term follow-up is not yet available. The toxicity of this regimen was acceptable, with none of the patients developing serious infections.

Elter et al extended these observations to a larger cohort of patients with relapsed or refractory B-CLL. Thirty-six patients were treated with alemtuzumab 30 mg/d iv and FAMP 30 mg/m²/d iv on 3 consecutive days every 28 days for a total of 6 cycles (4 cycles in the first 14 patients). The OR and CR rates were 83% and 30% respectively. The median OS was 35.6 months for all patients, with a time to progression of 22 months in patients who achieved a CR and 13 months for patients who achieved a PR. The treatment was well tolerated with acceptable infectious morbidity. Based upon these results, a phase III study comparing FAMP alone to FAMP plus alemtuzumab is currently underway in Europe.

Subsequently the M.D. Anderson group explored combination of alemtuzumab plus FAMP with CTX and rituximab with the goal of improving CR rate and eliminating MRD. Wierda et al reported the preliminary results of a phase II trial in which 31 patients with pre-treated B-CLL were treated with CTX (250 mg/m²/d days 3–5), FAMP (25 mg/m²/d days 3–5 i.v.) alemtuzumab (30 mg day 1, 3, 5) and rituximab (500 mg/m² day 2), every 28 days for 6 cycles. Twenty-one patients were evaluable for response and after a median number of 3 cycles (range 1–6) the OR rate was 52%, with 3 patients achieving a CR (14%) and 8 patients achieving a PR (38%). CMV reactivation was noted in 5 of 21 patients. Based upon these results, CFAR regimen was tested in a larger phase II study in patients with high risk and NCI indication for frontline therapy. OR and CR rates were 95% and 71% respectively. All patients in CR and nPR and 3 of 4 in PR were free of disease in the bone marrow by three-color flow cytometry. There was no significant correlation between CR or OR and Rai stage, IgVH mutation status, FISH status, or ZAP70 or CD38 expression. Grade 3 or 4 neutropenia and thrombocytopenia were seen in 27% and 7% of courses respectively and major infections were seen in 2% of courses.

Montillo et al reported interesting results combining FAMP plus alemtuzumab with CTX (FCC schedule) in a phase II study in patients with B-CLL with relapsed or refractory disease after at least one line of treatment. Subcutaneous route of administration of alemtuzumab was adopted in this trial. The FCC regimen consisted of FAMP 40 mg/m²/d oral days 1–3, CTX 250 mg/m²/d oral days 1–3 and alemtuzumab 10 to 20 mg subcutaneous days 1–3. This combination was repeated on day 29 for up to 6 cycles. Among the 25 patients enrolled OR rate was 79%, with 37% patients achieving CR. Grade III-IV neutropenia episodes were observed in 43% of the administered courses while grade III-IV thrombocytopenia episodes were detected only in 8% of cycles. Four major infections were recorded. Similar OR and CR rate have been obtained by Elter with the same combination. Two phase III studies comparing FC to FC plus alemtuzumab and FCR to FC plus alemtuzumab are currently ongoing in Europe by HOVON and GOELAMS respectively.

Another monoclonal antibody tested in B-CLL is Lumiliximab an anti-CD23 with human IgG1 constant regions and macaque variable regions. Preclinical data demonstrated that lumiliximab enhanced both FAMP- and rituximab-mediated apoptosis in B-CLL cells.

Preliminary results of phase 1/2, open-label, dose-escalation, multicenter study evaluating lumiliximab + FCR for relapsed CD23+ B-CLL have been reported. Treatment has been completed and follow-up is ongoing. Thirty-one patients received either 375 mg/m² or 500 mg/m² of lumiliximab in...
combination with a 28-day cycle of FCR for up to 6 cycles. The most common adverse events included nausea (77%), pyrexia (61%), chills (55%), neutropenia (55%), and fatigue (48%). Twenty patients (65%) experienced a Grade III or IV event. CR was achieved in 48% of patients with an OR rate of 71%. A comparison with data reported using FCR alone in relapsed or refractory B-CLL demonstrated that Lumiliximab + FCR has an acceptable safety profile. Moreover, it does not appear to increase the toxicity (including myelosuppression) of the FCR regimen, and compares favorably with the CR rate of the FCR regimen alone.

Studies testing FAMP combined with monoclonal antibodies are listed in Table 5.

**FAMP in allogeneic stem cell transplantation**

Allogeneic stem cell transplantation (alloSCT) is used for the treatment of various hematological malignancies. The standard approach has involved the use of a conditioning regimen, comprising myeloablative doses of chemo-radiotherapy, to eradicate the underlying malignancy and eliminate the host’s bone marrow in preparation for allogeneic graft, which functions primarily as a bone marrow rescue. More recently it has been suggested that the complete eradication of tumor cells is largely mediated by an immune-mediated destruction of malignant cells by donor lymphocytes, termed the graft-versus-leukemia (GVL) or graft-vs-tumor (GVT) effect. Replacing high-dose myeloablative therapy with a nonmyeloablative conditioning regimen would allow treatment of those patients who are too old or medically unfit to qualify for conventional alloSCT. The aim of non-myeloablative alloSCT is to use a low intensity preparative regimen to induce sufficient immunosuppression in the recipient to allow engraftment of allogeneic stem cells to prevent graft rejection. The non-myeloablative regimen does not completely eliminate host-derived cells, but over a period of time allogeneic lymphocytes act to eliminate residual hematopoietic and malignant cells. The drugs used in non-myeloablative conditioning regimens are generally chosen because they have some activity against the target malignancy and also provide sufficient immunosuppression to allow engraftment of allogeneic stem cells.

FAMP has been widely used in non-myeloablative conditioning regimens because of its immunosuppressive and antitumor activity. Non-myeloablative combination regimens with FAMP and other cytotoxic agents have been used in patients with various hematological diseases, including AML, chronic myeloid leukemia (CML), B-CLL, non-Hodgkin’s lymphoma (NHL), Hodgkin’s disease (HD), acute lymphoid leukemia (ALL) and multiple myeloma. The objective of achieving donor engraftment using a FAMP-based non-myeloablative conditioning regimen was achieved in all the studies reviewed. More recently, the addition of the monoclonal antibody alemtuzumab to a FAMP-based protocol has shown to reduce the incidence of GVHD, warranting further investigation in a randomized trial.

The main studies using FAMP-based regimen as non-myeloablative conditioning in B-CLL patients are reported in Table 6.

**Adverse events**

The most frequent adverse events associated with standard-dose iv FAMP regimens are myelosuppression (neutropenia, thrombocytopenia and anemia) and infection (typically respiratory tract infections and fever). Myelosuppression is the major dose-limiting adverse effect. NCI grade IV hematological toxicity was reported in 43% of patients receiving FAMP monotherapy for advanced-stage refractory B-CLL. In large-scale randomized studies, neutropenia, thrombocytopenia and anemia (WHO grade III/IV) occurred in 19%, 14% and 7% of FAMP treatment cycles, respectively, and affected 38, 15% and 18% of patients, respectively, during the first 6 treatment cycles. Severe (Grade III or IV) neutropenia tended to be more frequent with FAMP than with CHL (27% vs 19%). Treatment with FAMP leads to a decrease in the CD4/CD8 ratio for an extensive period of time, exceeding even 24 months. In consequence, infections, including opportunistic ones, are frequent events and infections with fatal outcome have been reported. FAMP-associated infection affects approximately 5% of patients with B-CLL, is accompanied by a sustained fall in T-cell numbers, and is exacerbated by coadministration of prednisone. Prolonged immunosuppression related to FAMP treatment may increase the risk of second malignancies. A retrospective analysis performed by Cheson et al in which they compared secondary tumours in B-CLL patients treated with FAMP, shows that this agent does not increase the risk of secondary neoplasms.

Also MDS and secondary AML (sAML) are rarely reported following FAMP monotherapy and no such cases were reported in 3 large cohorts of patients receiving FAMP.
### Table 5 Results of clinical trials on B-CLL with fludarabine and monoclonal antibody

| References | Comp study | No of evaluable pts | Prior therapy | Treatment regimen | Clinical response | Survival/duration of response |
|------------|------------|---------------------|---------------|-------------------|------------------|-------------------------------|
| Byrd et al79 | yes | 104 | no | FAMP 25 mg/m² iv d1–5 q 4 wk × 6 cycles followed by R 375 mg/m² iv × 4 doses (n, 53) | 47 | PFS 28%, OS 96% at 23 mo |
| Byrd et al82 | yes | 282 | no | FAMP 25 mg/m² iv d1–5 + R 375 mg/m² iv × 6 cycles followed by R 375 mg/m²/wk × 4 doses (n, 51) | 38 | PFS 67%, OS 93% at 2 yrs |
| Wierda et al80 | no | 177 | yes | FAMP 25 mg/m² iv d1/2–3/4 + CTX 250 mg/m² iv d1/2–3/4 + R 375–500 mg/m² iv d1 q 4 wk | 35 | 2 yr median PFS |
| Keating et al81 | no | 224 | no | FAMP 25 mg/m² iv d1/2–3/4 + CTX 250 mg/m² iv d1/2–3/4 + R 375–500 mg/m² iv d1 q 4 wk | 70 | TTF 69% at 4 yrs |
| Hallek et al85 | yes | 761 (for resp.) 787 (for PFS) 871 (for OS) | no | FAMP 25 mg/m² iv d1/2–3/4 + CTX 250 mg/m² iv d1/2–3/4 + R 375–500 mg/m² iv d1 q 4 wk | 52 | 2 yr median PFS |
| Foon et al86 | no | 48 | no | FAMP 20 mg/m² d1–3 + CTX 150 mg/m² d1–3 + R-500 mg/m² d1 and d14 q 4 wk; maintenance R-500 mg/m² q3 mo until progression | 79 | 22.3 mo median PFS |
| Bosch et al88 | no | 72 | no | FAMP 25 mg/m² iv d1/2–3/4 + CTX 250 mg/m² iv d1/2–3/4 + MIT 6 mg/m² iv d1 + R 375–500 mg/m² iv d1 q 4 wk | 82 | na |
| Tsimberidou et al87 | no | 50 (30 B-CLL 20 RS) | yes | O 17.5, 20, or 25 mg/m² iv d1–4 + FAMP 30 mg/m² iv d2–3 + ara-C 1 g/m² iv d2–3 + R 375 mg/m² d1 or d3 q 4 wk | 0 (B-CLL) 10 (RS) | TTF 47%, OS 89% at 6 mo (B-CLL) TTF 54%, OS 59% at 6 mo (RS) |
| Kennedy et al89 | no | 6 | yes | FAMP dose not applicable A dose not applicable | 17 | na |
| Elter et al94 | no | 36 | yes | A 30 mg iv + FAMP 30 mg/m² iv d1–3 q 4 wk | 31 | 35.6 mo median OS |
| Wierda et al96 | no | 21 | no | CTX 200 mg/m² d3–5 + FAMP 20 mg/m² d3–5 A 30 mg iv d1, 3, 5 R 375–500 mg/m² d2 q 4 wk | 71 | 12.9 mo median PFS |
| Montillo et al97 | no | 19 | yes | FAMP 40 mg/m² os d1–3 + CTX 250/m² os d1–3 + A 10–20 mg sc d1–3 | 37 | na |
| Elter et al98 | no | 20 | yes | FAMP 25 mg/m² iv d1–3 + CTX 200 mg/m² iv d1–3 + A 30 mg sc d1–3 | 25 | na |
| Byrd et al99 | yes | 31 | yes | Lu 375–500 mg/m² + FAMP 25 mg/m² iv d1/2–3/4 + CTX 250 mg/m² iv d1/2–3/4 + R 375–500 mg/m² iv d1 q 4 wk | 48 | na |

**Abbreviations:** Comp, comparative; RS, Richter's syndrome; resp., response; CR, complete remission; OR, overall response; OS, overall survival; PFS, progression-free survival; TTF, time to treatment failure; FAMP, fludarabine; MIT, mitoxantrone; ara-C, cytarabine; R, Riuximab; O, oxaliplatin; A, alemtuzumab; Lu, lumiliximab; d, days; mo, months; wk, weeks; q, every; iv, intravenous; os, oral; sc, subcutaneous; pts, patients; na, not applicable.
as initial therapy for B-CLL and only a single case was recorded among 724 patients receiving FAMP as salvage therapy for B-CLL. However, the combination of FAMP with CTX or other DNA damaging agents or following intensification with transplant procedure may increase the risk of MDS/sAML due to synergistic effects in the induction and inhibition of DNA damage.

Some reports suggest that FAMP may induce autoimmune hemolytic anemia (AIHA) in patients with B-CLL despite the reduction in leukemic clone. In the study performed by French Cooperative Group newly occurring AIHA was observed in only 2 patients treated with FAMP. Leporrier et al reported true AIHA only in 3% of the patients treated with CHOP, 1.5% treated with CAP and 1.5% treated with FAMP. Also in the LRFCLL4 trial the frequency of AIHA at completion of treatment was no different between CHL (12%) and FAMP (11%), and the lowest rate was noted after FAMP plus CTX administration (5%).

These findings suggest that FAMP plus CTX might have a protective effect, supporting similar observations of a study by the GCLLSG. Although, the results of the prospective multicenter randomized studies do not support the conclusion that the risk of AIHA is higher in the B-CLL patients treated with FAMP than in patients treated with CHL or other alkylating agents based regimens, the AIHA after FAMP could be more severe and more difficult to treat as suggested by the fatal events observed in the LRFCLL4 trial.

Pure red cell aplasia (PRCA) occurs in approximately 5% of B-CLL patients, most often in the course of disease, but also at presentation. The influence of FAMP on PRCA in patients with B-CLL has not been definitely defined yet.

The influence of prior treatment on the development of an aggressive NHL during the course of B-CLL (Richter’s syndrome) is unclear. Cheson et al found 18 (3.0%) patients with NHL among 595 patients treated with FAMP. In a retrospective analysis of 1487 B-CLL patients Richter’s syndrome was observed in 1% of cases in a group treated with cladribine, 0.9% in a group treated with alkylating agents and 0.6% in a group treated with cladribine + alkylating agents. The estimation of real incidence of Richter’s syndrome in patients treated with purine analogs needs further observation and longer follow-up.

Although there are reports documenting that FAMP impairs PBSC mobilization, this is still a much-discussed issue. It has been shown that other factors may affect the ability to mobilize stem cells: the number of prior therapeutic regimens, the disease stage at the time of mobilization, the
quality of response to FAMP. An early report from the EBMT indicated that FAMP did not impair progenitor cell mobilization, although better results were obtained early in the course of the disease and after two months from the last cycle of treatment. However, 2 reports have identified that prior FAMP therapy in patients with lymphoproliferative disease may be associated with difficulties in obtaining adequate progenitor cell numbers. It is possible that more effective mobilization strategies, and also more intensive cytoreductive therapy to achieve better disease control prior to attempting mobilization might help yield an adequate harvest in an even greater proportion of patients.

**Conclusion**

The increased knowledge of the biological and clinical features of B-CLL has been mirrored by the development of therapeutic agents that are more active than previous approaches. In this setting, FAMP has made the most significant impact on how we manage B-CLL today. Compared to traditional strategies, FAMP has improved remission rates and lengthened response duration, and has rapidly become established as the gold standard of care in B-CLL.

Furthermore FAMP has been shown to have a synergistic/biochemical modulating effect, with other chemotherapeutic agents and, more recently, with monoclonal antibodies. Thus, FAMP serves as a paradigm for the development of antancer therapy with rational combinations in modern therapeutic regimens.

The data reviewed indicate that FAMP administered in combination regimens may improve quality and rates of response, compared with FAMP in monotherapy in both pre-treated and untreated B-CLL patients. Although FC combination demonstrated exciting results in terms of OR and CR rates ranging from 74% to 94% and from 23% to 38% respectively, no difference was detected in survival.

Recently, eradication of MRD in B-CLL has been reported to be associated with prolonged survival. The development of such a wide variety of novel ‘targeted’ therapies for B-CLL and in particular of monoclonal antibody promises to make the goal of achieving MRD-negative remissions a reality for a large proportion of patients. The combination of FAMP/CTX/mitoxantrone and FAMP combinations with rituximab or alemtuzumab, might be promising, since a relevant number of complete molecular remissions are achieved with these drugs. The precise role of FAMP combinations within the overall treatment strategy remains to be determined. However, it is worth mentioning the results recently reported of trial CLL8 GCLLSG suggesting that FCR combination might become the new standard first-line treatment for physically fit B-CLL patients.

Combination of FAMP with other drugs rather than chemotherapeutic agents such as oblimersen or thalidomide warrants further investigation.

Increased clinical use of FAMP has highlighted its potential toxic effects, primarily myelo- and immuno-suppression. However, myelosuppression can be managed, even with the use of growth factors, and infectious complications can be prevented with adequate prophylaxis.

The most recent improvement in FAMP therapy is the development of an oral formulation with equivalent efficacy and tolerability to the iv preparation, coupled with the advantage of improved convenience of administration (for both patient and physician) and potentially superior cost effectiveness.

**Disclosures**

The authors have no conflicts of interest to declare.

**References**

1. CLL Trialists’ Collaborative Group. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. *J Natl Cancer Inst*. 1999;91:861–868.

2. Barrueco JR, Jacobsen DM, Chang C-H, et al. Proposed mechanism of therapeutic selectivity of 9-β-D-arabinofuranosyl-2-fluoroadenine against murine leukemia based upon lower capacities for transport and phosphorylation in proliferative intestinal epithelium compared to tumor cells. *Cancer Res*. 1987;47:700–706.

3. Ross SR, McTavish D, Faudoa D. Fludarabine: a review of its pharmacological properties and therapeutic potential in malignancy. *Drugs*. 1993;45:737–759.

4. Plunkett W, Gandhi V. Cellular metabolism of nucleoside analogs in CLL: implications for drug development. In: Cheson B, editor. Chronic lymphocytic leukemia – scientific advances and clinical developments. New York: Marcel Dekker. 1992. p. 197–219.

5. Plunkett W, Gandhi V, Huang P, et al. Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapy. *Semin Oncol*. 1993;20:2–12.

6. Avramis VI, Plunkett W. Metabolism and therapeutic efficacy of 9-β-D-arabinofuranosyl-2-fluoroadenine against murine leukemia P388. *Cancer Res*. 1982;42:2587–2591.

7. Danhauser L, Plunkett W, Keating M, et al. 9-β-D-Arabinofturanosyl-2-fluoroadenine 5′-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukaemia and lymphoma. *Cancer Chemother Pharmacol*. 1996;18:145–152.

8. Kemenia A, Keating MJ, Plunkett W. Plasma and cellular bioavailability of oral fludarabine. *Blood*. 1991;78:52a.

9. Danhauser L, Plunkett W, Liliemark J, et al. Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5′-monophosphate in patient with relapsed leukemia. *Leukemia*. 1987;1:638–643.

10. Kemenia A, Gandhi V, Shewach DS, et al. Inhibition of fludarabine metabolism by arabinosylcytosine during therapy. *Cancer Chemother Pharmacol*. 1992;31:193–199.

11. Gandhi V, Kemenia A, Keating MJ, et al. Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukaemia cells during fludarabine therapy. *Leuk Lymphoma*. 1993;10:49–56.
12. Keating MJ, O’Brien S, Kantarjian H, et al. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. *Blood.* 1993;81:2878–2884.
13. Keating MJ, O’Brien S, Lerner S, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. *Blood.* 1998;92:1165–1171.
14. Foran JM, Oscier D, Orchard J, et al. Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with “low-grade” non-Hodgkin’s lymphoma and B-cell chronic lymphocytic leukemia. *J Clin Oncol.* 1999;17:1574–1579.
15. Oscier D, Orchard JA, Culligan D, et al. The bioavailability of oral fludarabine phosphate is unaffected by food. *The Hematol J.* 2001;2:316–321.
16. O’Rourke TJ, Burris HA, Rodriguez GJ, et al. Phase I pharmacokinetic and bioavailability study of five daily intravenous and oral doses of fludarabine phosphate in patients with advanced cancer. *Proc Am Soc Clin Oncol.* 1997;16:210.
17. Ogawa Y, Hotta T, Tobinai K, et al. Phase I and pharmacokinetic study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin’s lymphoma. *Ann Oncol.* 2006;17:330–333.
18. Brockman RW, Schabel JR, Montgomery JA. Biological activity of 9-β-D-arabinofuranosyl-2-fluoroadenine, a metabolically stable analog of 9-β-D-arabinofuranosyladenine. *Biochimica et Biophysica Acta.* 1997;26:1936–1981.
19. Plunkett W, Alexander L, Chubb S, et al. Comparison of the toxicity and metabolism of 9-β-D-arabinofuranosyl-2-fluoroadenine and 9-β-D-arabinofuranosyladenine in human lymphoblastoid cells. *Cancer Res.* 1980;40:2349–2345.
20. Plunkett W, Saunders P. Metabolism and action of purine nucleoside analogs. *Pharmacol Ther.* 1991;49:233–2368.
21. Catapano CV, Perrino FW, Fernandes DJ. Primer RNA chain termination induced by 9-β-D-arabinofuranosyl-2-fluoroadenine 5′-triphosphate: a mechanism for DNA synthesis inhibition. *J Biol Chem.* 1993;268:7179–7185.
22. Parker W, Cheng YC. Inhibition of DNA primase by nucleoside triphosphates and their arabinofuranosyl analogs. *Mol Pharmacol.* 1987;31:144–151.
23. Parker WB, Bapat AR, Shen J-X, et al. Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases, DNA primase and ribonucleotide reductase. *Mol Pharmacol.* 1988;34:485–491.
24. Tseng WC, Derse D, Cheng Y-C, et al. In vitro activity of 9-β-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells. *Mol Pharmacol.* 1982;21:474–477.
25. White L, Shaddix SC, Brockman RW, et al. Comparison of the actions of 9-β-D-arabinofuranosyl-2-fluoroadenine and 9-β-D-arabinofuranosyladenine on target enzymes from mouse tumor cells. *Cancer Res.* 1982;42:2260–2264.
26. Spriggs D, Robbins G, Mitchell T, et al. Incorporation of 9-β-D-arabinofuranosyl-2-fluoroadenine into HL-60 cellular RNA and DNA. *Biochem Pharmacol.* 1986;35:247–252.
27. Huang P, Chubb S, Plunkett W. Termination of DNA synthesis by 9-β-D-arabinofuranosyl-2-fluoroadenine: a mechanism for cytotoxicity. *J Biol Chem.* 1990;265:16617–16625.
28. Huang P, Plunkett W. Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. *Chemother Pharmacol.* 1995a;36:181–188.
29. Huang P, Robertson LE, Wright S, et al. High molecular weight DNA fragmentation: a critical event in nucleoside analog-induced apoptosis in leukemia cells. *Clin Cancer Res.* 1995b;1:1005–1013.
30. Huang P, Ballal K, Plunkett W. Biochemical characterization of the protein activation responsible for high molecular weight DNA fragmentation during drug-induced apoptosis. *Cancer Res.* 1997;57:3407–3414.
31. Robertson LE, Chubb S, Meyn RE, et al. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-β-D-arabinosyl-2-fluoroadenine. *Blood.* 1993;81:143–150.
32. Keating MJ, Kantarjian H, Talpaz M, et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. *Blood.* 1989;74:19–25.
33. Sorensen JM, Vena DA, Fallavollita A, et al. Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report. *J Clin Oncol.* 1997;15:458–465.
34. Keating MJ, Kantarjian H, O’Brien S, et al. Fludarabine: a new agent with marked cytodestructive activity in untreated chronic lymphocytic leukemia. *J Clin Oncol.* 1991;9:44–49.
35. Clavio M, Migliño M, Sprario M, et al. First-line fludarabine treatment of symptomatic chronic lymphoproliferative diseases: clinical results and molecular analysis of minimal residual disease. *Eur J Haematol.* 1998;61:197–203.
36. Stelitano C, Morabito F, Kropp MG, et al. Fludarabine treatment in B-cell chronic lymphocytic leukemia: response, toxicity and survival analysis in 47 cases. *Haematologica.* 1999;84:317–323.
37. Boogaerts MA, Van Hoof A, Catsby SK, et al. Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia. *J Clin Oncol.* 2001;19:4252–4258.
38. Rossi JF, Van Hoof A, de Boeck K, et al. Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukaemia. *J Clin Oncol.* 2004;22:1260–1267.
39. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukaemia. *N Engl J Med.* 2000;343:1750–1757.
40. Johnson S, Smith AG, Löffler H, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. *Lancet.* 1996;347:1432–1438.
41. Leporrier M, Chevret S, Cazin B, et al. Randomized comparison of fludarabine, CAP and CHOP in 938 previously untreated stage B and C chronic lymphocytic leukaemia patients. *Blood.* 2001;98:2319–2325.
42. Sprario M, Chiurazzi F, Cassibba V, et al. Multicentric prospective randomised trial of fludarabine versus chlorambucil and prednisone in previously untreated patients with active B-chronic lymphocytic leukaemia (B-CLL): first interim report. *Br J Haematol.* 1998;102:191.
43. Eichhorst BF, Busch R, Obwandner T, et al. Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group. *J Clin Oncol.* 2007;25:1722–1731.
44. O’Brien S, Kantarjian H, Beran M, et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. *Blood.* 1993;82:1695–1700.
45. Döhner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. *Blood.* 1995;85:1580–1589.
46. Valgáhon M, Giraldo P, Agire X, et al. p53 Aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV. *Br J Haematol.* 2005;129:53–59.
47. Bellosillo B, Villamor N, Colomer D, et al. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. *Blood.* 1999;94:2836–2843.
48. Koehl U, Li L, Nowak B. Fludarabine and cyclophosphamide: synergetic cytotoxicity associated with inhibition of interstrand cross-link removal. *Proc Am Assoc Cancer Res.* 1997;38:2.
49. Gandhi V, Nowak B, Keating MJ, et al. Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy. *Blood.* 1989;74:2070–2075.
50. Seymour JF, Huang P, Plunkett W, et al. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule. *Clin Cancer Res.* 1996;2:653–658.
51. Yang L-Y, Li L, Keating MJ, et al. Plunkett W. Arabinosyl-2-fluorodeine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair. Mol Pharmacol. 1995;47:1072–1079.

52. Zaffaroni N, Orlandi L, Gornati D, et al. Fludarabine as a modulator of cisplatin activity in human tumour primary cultures and established cell lines. Eur J Cancer. 1996;32A:1766–1773.

53. Knauf WU, Kreuser ED, Pottgiesser E, et al. In vitro and in vivo effectiveness of fludarabine in B-cell chronic lymphocytic leukemia (B-CLL). Ann Hematol. 1992;65:880.

54. Elias L, Stock-Novack D, Head DR, et al. A phase 1 trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: a Southwest Oncology Group study. Leukemia. 1993;7:361–365.

55. Weiss M, Spiess T, Berman E, et al. Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukaemia. Leukemia. 1994;8:1290–1293.

56. Morrison VA, Rai KR, Peterson BL, et al. Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. J Clin Oncol. 2001;19:3611–3621.

57. O’Brien S, Kantarjian HM, Cortes J, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol. 2001;19:1414–1420.

58. Flinn IW, Jemiai Y, Bennett JM, et al. Fludarabine and cyclophosphamide achieves high complete response rate in patients with previously untreated chronic lymphocytic leukemia: ECOG 1997. Blood. 2000;98:633a.

59. Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukaemia. Blood. 2006;107:885–891.

60. Stilgenbauer S, Eichhorst BF, Busch R, et al. Biological and Clinical Markers for Outcome after Fludarabine (F) or F Plus Cyclophosphamide (FC) – Comprehensive Analysis of the CLL4 Trial of the GCLLSG. Blood. 2008;112:2089a.

61. Flinn IW, Neuberg DS, Grever MR, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukaemia: US Intergroup Trial E2997. J Clin Oncol. 2007;25:793–798.

62. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet. 2007;370:230–239.

63. Cazin B, Divine M, Leprêtre S, et al. High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemia. Br J Haematol. 2008;143:54–59.

64. Laurenti L, Tarnani M, De Padua L, et al. Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration. Ann Hematol. 2008;87:891–898.

65. Bosch F, Ferrer A, Lopez-Guillermo A, et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukemia. Br J Haematol. 2002;119:976–984.

66. Bosch F, Ferrer A, Villamor N, et al. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication. Clin Cancer Res. 2008;14:155–161.

67. Mauro FR, Foà R, Meloni G, et al. Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients. Haematologica. 2002;87:926–933.

68. Robertson LE, O’Brien S, Kantarjian H, et al. Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia, Leukemia. 1995;9:943–945.

69. Rummel MJ, Kafer G, Pfleundschuh M, et al. Fludarabine and epirubicin in the treatment of chronic lymphocytic leukemia: a German multicenter phase II study. Ann Oncol. 1999;10:183–188.

70. Rummel MJ, Stilgenbauer S, Gamm H, et al. Fludarabine versus fludarabine plus epirubicin in the treatment of chronic lymphocytic leukemia (CLL) – preliminary results of a randomized phase-III multicenter study. Blood. 2002;100:384a.

71. Gandhi V, Robertson LE, Keating MJ, et al. Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology. Cancer Chemother Pharmacol. 1994;34:30–36.

72. Giles FJ, O’Brien SM, Santini V, et al. Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study. Leuk Lymphoma. 1999;36:57–65.

73. O’Brien S, Moore JO, Boyd TE, et al. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukaemia. J Clin Oncol. 2007;25:1114–1120.

74. Chanman-Khan A, Miller KC, Takeshita K, et al. Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL). Blood. 2005;106:3348–3352.

75. Laurenti L, Piccioni P, Tarnani M, et al. Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pre-treated patients with chronic lymphocytic leukaemia. Leuk Res. 2007;31:253–256.

76. Huhns D, von Schilling C, Wilhelms M, et al. Rituximab therapy for patients with B chronic lymphocytic leukaemia. Blood. 2001;98:1326–1331.

77. Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol. 2001;19:2153–2164.

78. O’Brien S, Santarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukaemia. J Clin Oncol. 2001;19:2165–70.

79. Byrd JC, Peterson BL, Morrison VA et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukaemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003;101:6–14.

80. Wierda W, O’Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukaemia. J Clin Oncol. 2005;23:4070–4078.

81. Keating MJ, O’Brien S, Albirat M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4079–4088.

82. Byrd JC, Rai K, Peterson BL, Appelbaum FR, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood. 2005;105:49–53.

83. Tam CS, O’Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112:975–980.

84. Lin KI, Tam CS, Keating MJ, et al. Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. Blood. 2008;Dec 2 [Epub ahead of print].

85. Hallek M, Fingerle-Rowson G, Fink AM, et al. Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL). Blood. 2008;112:325a.

86. Foon KA, Boyadzis M, Land SR, et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2008;Dec 15 [Epub ahead of print].
103. Anderlini P, Giralt S, Andersson B, et al. Allogeneic stem cell trans-
102. Nagler A, Slavin S, Varadi G, et al. Allogeneic peripheral blood stem
101. Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-
99. Byrd J, Castro J, O’Brien S, et al. Comparison of results from a phase
98. Elter T, James R, Wendtner CM, et al. Consolidation with
97. Montillo M, Miqueleiz S, Tedeschi A, et al. Allemontuzumab as consoli-
dation after a response to fludarabine is effective in purging residual
disease in patients with chronic lymphocytic leukemia. J Clin Oncol.
96. Wierda W, Faderl S, O’Brien S, et al. Combined Cyclophosphamide,
95. Wierda W, O’Brien S, Ferrajoli A, et al. Immunosuppression and alemtu-
94. Elter T, Borchmann P, Schulz H, et al. Fludarabine in combination
93. Kennedy B, Rawstron A, Carter C, et al. Campath-1H and fludarabine in
combination are highly active in refractory chronic lymphocytic leukaemia. Blood. 2002;99:2245–2247.
92. Wendtner CM, Rutgen M, Schweighofer CD, et al. Comparison of
chemoimmunotherapy regimen for chronic lymphoid leukemia. Blood.
91. Montillo M, Tedeschi A, Miqueleiz S, et al. Allemontuzumab as consoli-
dation after a response to fludarabine is effective in purging residual

disease in patients with chronic lymphocytic leukemia. J Clin Oncol.
90. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with
chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol. 2007;25:5616–5623.
89. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab
(Campath-1H) in patients who have failed fludarabine: results of a
large international study. Blood. 2002;99:3554–3561.
88. Bosch F, Abriqueta P, Villamor N, et al. Rituximab, fludarabine,
fyclophosphamide, and mitoxantrone (RF-CM) is a highly active
chemoimmunotherapy regimen for chronic lymphocytic leukemia. Blood. 2008;112:2097a
87. Tsimeridou AM, Wierda WG, Plunkett W, et al. Phase I-II study of
oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy
in patients with Richter’s syndrome or fludarabine-refractory chronic
lymphocytic leukemia. J Clin Oncol. 2006;24:196–203.
86. Anaissie EJ, Kontoyiannis DP, O’Brien S, et al. Infections in patients
with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med. 1998;99:559–566.
85. Perez-Simon JA, Kottaridis PD, Martino R, et al. Nonmyeloablative
transplantation with or without alemtuzumab: comparison between
2 prospective studies in patients with lymphoproliferative disorders. Blood. 2002;100:3121–3127.
84. Bergmann L, Fenckel K, Jahn B, et al. Immunosuppressive effects
and clinical response of fludarabine in refractory chronic lymphocytic
leukemia. Ann Oncol. 1993;4:371–375.
83. Wierda W, O’Brien S, Ferrajoli A, et al. Combined Cyclophosphamide,
and Alemtuzumab (FCC), an Active Regimen for
progenitor cell transplantation.
82. Ricci et al. conditioning for allogeneic transplantation in patients with multiple
myeloma. Bone Marrow Transplant. 2002;30:367–373.
81. Byrd J, Castro J, O’Brien S, et al. Comparison of results from a phase
80. Anaissie EJ, Kontoyiannis DP, O’Brien S, et al. Infections in patients
with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med. 1998;99:559–566.
79. Cheson BD. Infections and immunosuppressive complications of purine
analog therapy. J Clin Oncol. 1995;13:2431–2448.
78. Busuttil DP, Chasty RC, Copplestone JA, et al. Infections complicating
treatment of lymphoid malignancies with fludarabine. Br J Haematol. 1996;93 Suppl 1:69.
77. Montillo M, Vena DA, Barrett J, et al. Second malignancies as a conse-
quence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol. 1999;17:2454–2460.
76. Tam CS, Seymour JF, Prince HM, et al. Treatment-related myelodys-
plasia following fludarabine combination chemotherapy. Haematologica. 2006;91:1546–1550.
75. Gribben JG, Zahlrieh D, Stephans K, et al. Autologous and allogeneic
stem cell transplantation for poor-risk chronic lymphocytic leukemia. Blood. 2005;106:4389–4396
74. Milligan DW, Fernandes S, Dasgupta R, et al. Results of the MRC
pilot study show autografting for younger patients with chronic lymph-
ocyic leukaemia is safe and achieves a high percentage of molecular
responses. Blood. 2005;105:397–404
73. Mauro FR, Foa R, Cerretti R et al. Autoimmune hemolytic anemia in
chronic lymphocytic leukemia: clinical, therapeutic and prognostic
features. Blood. 2000;95:2786–2792.
72. Robak T, Blonski JZ, Gora-Tybor J, et al. Second malignancies and
Richter’s syndrome in patients with chronic lymphocytic leukemia
treated with cladribine. Eur J Cancer. 2004;40:383–389.
71. Michallet M, Thibault A, Dreger P, et al. Peripheral blood stem cell
(PBSC) mobilization and transplantation after fludarabine therapy
in chronic lymphocytic leukaemia (CLL): a report of the European
Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukaemias Working Party (CLWP). Br J Haematol. 2000;108:595–601.
70. Morgan SJ, Seymour JF, Grigg A, et al. Predictive factors for success-
ful stem cell mobilization in patients with indolent lymphopro-
liferative disorders previously treated with fludarabine. Leukemia.
2004;18:1034–1038.
69. Micaleff IN, Apostolidis J, Rohatiner AZ, et al. Factors which predict
unsuccessful mobilization of peripheral blood progenitor cells follow-
ing G-CSF alone in patients with non-Hodgkin’s lymphoma. Hematol J. 2000;1:367–373.
68. Montillo M, Tedeschi A, Rossi V, et al. Successful CD34+ cell mobi-
lization by intermediate-dose Ara-C in chronic lymphocytic leukemia
patients treated with sequential fludarabine and Campath-1H. Leuke-
mia. 2004;18:57–62.
67. Hallek M, Schmitt B, Wilhelm M, et al. Fludarabine plus cyclophos-
phamide is an efficient treatment for advanced chronic lymphocytic
leukemia (CLL): results of a phase II study of the German CLL Study
Group. Br J Haematol. 2001;114:342–348.
66. Tsimeridou AM, Keating MJ, Giles FJ, et al. Fludarabine and mito-
xantrone for patients with chronic lymphocytic leukemia. Cancer.
2004;100:2583–2591.
65. Dreger P, Brand R, Hansz J, et al. Treatment-related mortality and
graft-versus-leukemia activity after allogeneic stem cell transplantation
for chronic lymphocytic leukemia using intensity-reduced condition-
ing. Leukemia. 2003;17:841–848.
64. Sorror ML, Maris MB, Sandmaier BM, et al. Hematopoietic
cell transplantation after nonmyeloablative conditioning for
advanced chronic lymphocytic leukemia. J Clin Oncol. 2005;23:
3819–3829.
124. Brown JR, Kim HT, Li S, et al. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. *Biol Blood Marrow Transplant*. 2006;12:1056–1064.

125. Delgado J, Thomson K, Russell N, et al. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study. *Blood*. 2006;107:1724–1730.

126. Schetelig J, Thiede C, Bornhauser M, et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. *J Clin Oncol*. 2003;21:2747–2753.
